ORG Partners LLC Raises Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

ORG Partners LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 66,317 shares of the biopharmaceutical company’s stock after buying an additional 225 shares during the period. ORG Partners LLC’s holdings in Gilead Sciences were worth $6,126,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of GILD. Bellevue Group AG raised its stake in shares of Gilead Sciences by 18.2% in the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock worth $3,859,000 after purchasing an additional 7,093 shares during the last quarter. Quantinno Capital Management LP grew its holdings in shares of Gilead Sciences by 149.5% during the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock worth $6,843,000 after buying an additional 48,910 shares in the last quarter. Legal & General Group Plc increased its stake in shares of Gilead Sciences by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after acquiring an additional 93,068 shares during the last quarter. IRON Financial LLC acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $830,000. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in Gilead Sciences by 12.9% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 323,011 shares of the biopharmaceutical company’s stock valued at $27,081,000 after buying an additional 36,895 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Trading Up 0.3 %

Gilead Sciences stock traded up $0.24 during mid-day trading on Friday, hitting $89.38. 2,007,397 shares of the stock were exchanged, compared to its average volume of 5,029,229. The stock has a market capitalization of $111.39 billion, a price-to-earnings ratio of 993.11, a PEG ratio of 2.24 and a beta of 0.18. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The firm’s fifty day simple moving average is $91.93 and its two-hundred day simple moving average is $83.06.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period last year, the business earned $2.29 EPS. Analysts forecast that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were paid a $0.77 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.45%. Gilead Sciences’s payout ratio is 3,422.22%.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares in the company, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 8,500 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $91.96, for a total value of $781,660.00. Following the completion of the sale, the chief financial officer now directly owns 132,373 shares in the company, valued at approximately $12,173,021.08. This represents a 6.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 453,734 shares of company stock valued at $41,902,086 over the last three months. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

GILD has been the topic of a number of research reports. UBS Group raised their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. BMO Capital Markets raised their price target on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Bank of America restated a “buy” rating and set a $109.00 price objective on shares of Gilead Sciences in a report on Tuesday, December 10th. Finally, Leerink Partners upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $74.00 to $96.00 in a research note on Monday, October 21st. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $97.96.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.